Argon plasma coagulation for Barrett’s esophagus with low-grade dysplasia: a randomized trial with long-term follow-up on the impact of power setting and proton pump inhibitor dose

Ewa Wronska; Marcin Polkowski; Janina Orlowska; Andrzej Mroz; Paulina Wieszczy; Jaroslaw Regula

doi:10.1055/a-1203-5930

Endoscopy, Table of Contents

Endoscopy 2021; 53(02): 123-132
DOI: 10.1055/a-1203-5930

Original article

Argon plasma coagulation for Barrett’s esophagus with low-grade dysplasia: a randomized trial with long-term follow-up on the impact of power setting and proton pump inhibitor dose

Ewa Wronska

¹Department of Gastroenterology, Hepatology and Oncology, Center of Postgraduate Medical Education, Warsaw, Poland

²Department of Gastroenterological Oncology, Maria Sklodowska-Curie Institute – Oncology Center, Warsaw, Poland

,

Marcin Polkowski

¹Department of Gastroenterology, Hepatology and Oncology, Center of Postgraduate Medical Education, Warsaw, Poland

²Department of Gastroenterological Oncology, Maria Sklodowska-Curie Institute – Oncology Center, Warsaw, Poland

,

Janina Orlowska

²Department of Gastroenterological Oncology, Maria Sklodowska-Curie Institute – Oncology Center, Warsaw, Poland

,

Andrzej Mroz

³Department of Pathomorphology, Center of Postgraduate Medical Education, Warsaw, Poland

⁴Department of Pathology and Laboratory Medicine, Maria Sklodowska-Curie Institute – Oncology Center, Warsaw, Poland

,

Paulina Wieszczy

¹Department of Gastroenterology, Hepatology and Oncology, Center of Postgraduate Medical Education, Warsaw, Poland

⁵Department of Cancer Prevention, Maria Sklodowska-Curie Institute – Oncology Center, Warsaw, Poland

,

Jaroslaw Regula

¹Department of Gastroenterology, Hepatology and Oncology, Center of Postgraduate Medical Education, Warsaw, Poland

²Department of Gastroenterological Oncology, Maria Sklodowska-Curie Institute – Oncology Center, Warsaw, Poland

› Author Affiliations

Abstract

Background This study evaluated the impact of power setting and proton pump inhibitor (PPI) dose on efficacy and safety of argon plasma coagulation (APC) of Barrett’s esophagus (BE) with low-grade dysplasia (LGD).

Methods 71 patients were randomized to APC with power set at 90 W or 60 W followed by 120 mg or 40 mg omeprazole. The primary outcome was the rate of complete (endoscopic and histologic) ablation of BE at 6 weeks. Secondary outcomes included safety and long-term efficacy.

Results Complete ablation rate in the 90 W/120 mg, 90 W/40 mg, and 60 W/120 mg groups was 78 % (18/23; 95 % confidence interval [CI] 61–95), 60 % (15/25; 95 %CI 41–79), 74 % (17/23; 95 %CI 56–92), respectively, at 6 weeks and 70 % (16/23; 95 %CI 51–88), 52 % (13/25; 95 %CI 32–72), and 65 % (15/23; 95 %CI 46–85) at 2 years post-treatment (differences not significant). Additional APC was required in 28 patients (23 residual and 5 recurrent BE). At median follow-up of 108 months, 66/71 patients (93 %; 95 %CI 87–99) maintained complete ablation. No high-grade dysplasia or adenocarcinoma developed. Overall, adverse events (97 % mild) did not differ significantly between groups. Chest pain/discomfort was more frequent in patients receiving 90 W vs. 60 W power (P < 0.001). One patient had esophageal perforation and two developed stenosis.

Conclusions APC power setting and PPI dose did not impact efficacy and safety of BE ablation. Complete ablation of BE with LGD was durable in > 90 % of patients, without any evidence of neoplasia progression in the long term.

Full Text

References

References
1 Eluri S, Shaheen NJ. Barrett’s esophagus: diagnosis and management. Gastrointest Endosc 2017; 85: 889-903
2 Weusten B, Bisschops R, Coron E. et al. Endoscopic management of Barrett’s esophagus: European Society of Gastrointestinal Endoscopy (ESGE) Position Statement. Endoscopy 2017; 49: 191-198
3 di Pietro M, Fitzgerald RC. BSG Barrett’s Guidelines Working Group. Revised British Society of Gastroenterology recommendation on the diagnosis and management of Barrett’s oesophagus with low-grade dysplasia. Gut 2018; 67: 392-393
4 Shaheen NJ, Falk GW, Iyer PG. et al. ACG Clinical Guideline: diagnosis and management of Barrett’s esophagus. Am J Gastroenterol 2016; 111: 30-50
5 Wani S, Rubenstein JH, Vieth M. et al. Diagnosis and management of low-grade dysplasia in Barrett’s esophagus: expert review from the Clinical Practice Updates Committee of the American Gastroenterological Association. Gastroenterology 2016; 151: 822-835
6 Fitzgerald RC, di Pietro M, Ragunath K. et al. British Society of Gastroenterology guidelines on the diagnosis and management of Barrett’s oesophagus. Gut 2014; 63: 7-42
7 Wani S, Qumseya B, Sultan S. et al. Endoscopic eradication therapy for patients with Barrett’s esophagus-associated dysplasia and intramucosal cancer. Gastrointest Endosc 2018; 87: 907-931.e909
8 Shaheen NJ, Sharma P, Overholt BF. et al. Radiofrequency ablation in Barrett’s esophagus with dysplasia. N Engl J Med 2009; 360: 2277-2288
9 Phoa KN, van Vilsteren FG, Weusten BL. et al. Radiofrequency ablation vs endoscopic surveillance for patients with Barrett esophagus and low-grade dysplasia: a randomized clinical trial. JAMA 2014; 311: 1209-1217
10 Qumseya BJ, Wani S, Gendy S. et al. Disease progression in Barrett’s low-grade dysplasia with radiofrequency ablation compared with surveillance: systematic review and meta-analysis. Am J Gastroenterol 2017; 112: 849-865
11 Bright T, Watson DI, Tam W. et al. Prospective randomized trial of argon plasma coagulation ablation versus endoscopic surveillance of Barrett’s esophagus in patients treated with antisecretory medication. Dig Dis Sci 2009; 54: 2606-2611
12 Bright T, Watson DI, Tam W. et al. Randomized trial of argon plasma coagulation versus endoscopic surveillance for Barrett esophagus after antireflux surgery: late results. Ann Surg 2007; 246: 1016-1020
13 Sie C, Bright T, Schoeman M. et al. Argon plasma coagulation ablation versus endoscopic surveillance of Barrett’s esophagus: late outcomes from two randomized trials. Endoscopy 2013; 45: 859-865
14 Ackroyd R, Tam W, Schoeman M. et al. Prospective randomized controlled trial of argon plasma coagulation ablation vs. endoscopic surveillance of patients with Barrett’s esophagus after antireflux surgery. Gastrointest Endosc 2004; 59: 1-7
15 Manner H, Rabenstein T, Pech O. et al. Ablation of residual Barrett’s epithelium after endoscopic resection: a randomized long-term follow-up study of argon plasma coagulation vs. surveillance (APE study). Endoscopy 2014; 46: 6-12
16 Peerally MF, Bhandari P, Ragunath K. et al. Radiofrequency ablation compared with argon plasma coagulation after endoscopic resection of high-grade dysplasia or stage T1 adenocarcinoma in Barrett’s esophagus: a randomized pilot study (BRIDE). Gastrointest Endosc 2019; 89: 680-689
17 Kahaleh M, Van Laethem JL, Nagy N. et al. Long-term follow-up and factors predictive of recurrence in Barrett’s esophagus treated by argon plasma coagulation and acid suppression. Endoscopy 2002; 34: 950-955
18 Ferraris R, Fracchia M, Foti M. et al. Barrett’s oesophagus: long-term follow-up after complete ablation with argon plasma coagulation and the factors that determine its recurrence. Aliment Pharmacol Ther 2007; 25: 835-840
19 Milashka M, Calomme A, Van Laethem JL. et al. Sixteen-year follow-up of Barrett’s esophagus, endoscopically treated with argon plasma coagulation. United European Gastroenterol J 2014; 2: 367-373
20 Madisch A, Miehlke S, Bayerdorffer E. et al. Long-term follow-up after complete ablation of Barrett’s esophagus with argon plasma coagulation. World J Gastroenterol 2005; 11: 1182-1186
21 Sampliner RE. Updated guidelines for the diagnosis, surveillance, and therapy of Barrett’s esophagus. Am J Gastroenterol 2002; 97: 1888-1895
22 Cotton PB, Eisen GM, Aabakken L. et al. A lexicon for endoscopic adverse events: report of an ASGE workshop. Gastrointest Endosc 2010; 71: 446-454
23 Byrne JP, Armstrong GR, Attwood SE. Restoration of the normal squamous lining in Barrett’s esophagus by argon beam plasma coagulation. Am J Gastroenterol 1998; 93: 1810-1815
24 Van Laethem JL, Cremer M, Peny MO. et al. Eradication of Barrett’s mucosa with argon plasma coagulation and acid suppression: immediate and mid term results. Gut 1998; 43: 747-751
25 Schulz H, Miehlke S, Antos D. et al. Ablation of Barrett’s epithelium by endoscopic argon plasma coagulation in combination with high-dose omeprazole. Gastrointest Endosc 2000; 51: 659-663
26 Mork H, Barth T, Kreipe HH. et al. Reconstitution of squamous epithelium in Barrett’s oesophagus with endoscopic argon plasma coagulation: a prospective study. Scand J Gastroenterol 1998; 33: 1130-1134
27 Pereira-Lima JC, Busnello JV, Saul C. et al. High power setting argon plasma coagulation for the eradication of Barrett’s esophagus. Am J Gastroenterol 2000; 95: 1661-1668
28 Basu KK, Pick B, Bale R. et al. Efficacy and one year follow up of argon plasma coagulation therapy for ablation of Barrett’s oesophagus: factors determining persistence and recurrence of Barrett’s epithelium. Gut 2002; 51: 776-780
29 Manner H, May A, Miehlke S. et al. Ablation of nonneoplastic Barrett’s mucosa using argon plasma coagulation with concomitant esomeprazole therapy (APBANEX): a prospective multicenter evaluation. Am J Gastroenterol 2006; 101: 1762-1769
30 Pedrazzani C, Catalano F, Festini M. et al. Endoscopic ablation of Barrett’s esophagus using high power setting argon plasma coagulation: a prospective study. World J Gastroenterol 2005; 11: 1872-1875
31 Kelty CJ, Ackroyd R, Brown NJ. et al. Endoscopic ablation of Barrett’s oesophagus: a randomized-controlled trial of photodynamic therapy vs. argon plasma coagulation. Aliment Pharmacol Ther 2004; 20: 1289-1296
32 Hage M, Siersema PD, van Dekken H. et al. 5-aminolevulinic acid photodynamic therapy versus argon plasma coagulation for ablation of Barrett’s oesophagus: a randomised trial. Gut 2004; 53: 785-790
33 Sharma P, Wani S, Weston AP. et al. A randomised controlled trial of ablation of Barrett’s oesophagus with multipolar electrocoagulation versus argon plasma coagulation in combination with acid suppression: long term results. Gut 2006; 55: 1233-1239
34 Pandey G, Mulla M, Lewis WG. et al. Systematic review and meta-analysis of the effectiveness of radiofrequency ablation in low grade dysplastic Barrett’s esophagus. Endoscopy 2018; 50: 953-960
35 Komanduri S, Muthusamy VR, Wani S. Controversies in endoscopic eradication therapy for Barrett’s esophagus. Gastroenterology 2018; 154: 1861-1875.e1861